Peptide Profile
Vesilute
Tissue-specific dipeptide bioregulator (Glu-Asp) that epigenetically normalizes urogenital function through chromatin remodeling, anti-inflammatory cytokine regulation, and smooth muscle tone restoration in the bladder and prostate
Dose Range
20-40mg
Frequency
Once daily
Route
Oral (capsule/tablet)
Cycle Length
12+ weeks
Onset
Gradual (3-4 weeks)
Evidence
Moderate
Compound Profile
Scientific & Efficacy Data
C9H14N2O7
Molecular Formula
262.2 g/mol
Molecular Weight
Short plasma half-life typical of dipeptides (minutes); biological effects persist for weeks to months through epigenetic gene regulation; metabolized to constituent amino acids via standard pathways
Half-Life
High oral bioavailability for a dipeptide — absorbed intact by intestinal peptide transporter PepT1 (SLC15A1); ultra-short structure enables efficient cellular uptake and nuclear penetration
Bioavailability
3918-84-1
CAS #
99716
PubChem ID ↗
Developed By · 1990s (based on urogenital peptide extract research beginning in the 1980s)
Academic research consortium
Multiple research institutions
Primary Benefits
Amino Acid Sequence
Sequence not publicly available or proprietaryDosing
How much
do I take?
Starting Dose
20 mg once daily
Begin with the standard Khavinson bioregulator starting protocol. Take orally with water before breakfast. As an ultra-short dipeptide, Vesilute is efficiently absorbed by intestinal peptide transporters (PepT1/SLC15A1). Effects are gradual and cumulative — improvements in urinary function typically begin during the second week. Suitable for initial assessment of individual tolerance.
Standard Dose
20-40 mg daily (1-2 capsules)
Standard clinical protocol used in Russian bioregulator therapy for BPH and overactive bladder. Courses of 20-30 days with intervals of 2-6 months between courses. Epigenetic effects persist beyond the active treatment period. Can be combined with Prostamax for enhanced prostate support or Ventfort for vascular support. Track urinary symptom improvements (frequency, urgency, flow rate) to assess response.
Advanced Dose
40 mg daily (2 capsules)
Upper range protocol for moderate-to-significant urogenital symptoms. Often combined with complementary Khavinson bioregulators: Prostamax for additional prostate-specific support, Ventfort for vascular health, and Vilon for overall tissue regeneration. Courses may be repeated every 2-3 months for persistent symptoms. Extended use data from the Khavinson bioregulator clinical experience supports long-term safety of cyclic treatment.
Timing
Best time to take
Take Vesilute at the same time each day for consistent blood levels. Morning dosing with breakfast is often preferred, but follow your healthcare provider's specific instructions.
With food?
Vesilute can typically be taken with or without food. Taking it with a light meal may help reduce any GI discomfort. Avoid taking with grapefruit juice or high-fat meals unless specifically directed.
If stacking
Vesilute should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting Your Dose
Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
Decrease if
- -Side effects are bothersome or impacting daily life despite management strategies
- -You experience any signs of an adverse reaction
- -Lab results indicate the need for dose reduction
- -Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Suitability
Is this
right for me?
Best For
Supporting bladder health and urinary function in aging individuals
Vesilute is particularly well-suited for individuals focused on supporting bladder health and urinary function in aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Bioregulatory approach to benign prostatic hyperplasia (BPH) management
Vesilute is particularly well-suited for individuals focused on bioregulatory approach to benign prostatic hyperplasia (bph) management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing chronic urogenital inflammation through epigenetic mechanisms
Vesilute is particularly well-suited for individuals focused on reducing chronic urogenital inflammation through epigenetic mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Complementing standard urological treatments with peptide bioregulator therapy
Vesilute is particularly well-suited for individuals focused on complementing standard urological treatments with peptide bioregulator therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider Alternatives If
Who Should Avoid
Do not use if
- ×Known hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid)
- ×Pregnancy and breastfeeding — insufficient reproductive safety data
- ×Active urinary tract infection requiring antibiotic treatment — treat infection first
- ×Bladder or prostate malignancy — proliferative effects of peptide bioregulators may be contraindicated
Use with caution if
- !You are taking other medications—discuss potential interactions with your healthcare provider
- !You have a history of liver or kidney disease
- !You are elderly or have multiple medical conditions
- !You are planning surgery in the near future—inform your surgeon about Vesilute use
- !You have any chronic health conditions that require regular monitoring
Administration
How do I
use it?
Reconstitution
What you need
- •Vesilute in its prescribed form
- •Clean, dry storage container
- •Measuring device if applicable (oral syringe, measuring cup)
- •Calendar or reminder app for dosing schedule
Injection
Route
Vesilute is administered Oral (capsule/tablet)—no injection required
Best sites
- •Not applicable—this is not an injectable formulation
Technique
- 1.Follow the specific administration instructions for your Vesilute formulation
- 2.Take or apply as directed by your healthcare provider
- 3.Store properly between uses according to package instructions
Storage
Signs of degradation
Sample Daily Schedule
Safety
Is it
safe?
Safety Profile
Vesilute (fibroin-derived peptide from Bombyx mori silk) demonstrates favorable biocompatibility from cosmetic ingredient testing with minimal allergic or irritant potential despite its animal protein origin. Limited systemic absorption occurs topically, confining effects to dermal layers with low risk of systemic toxicity. Silk-derived peptides have been used in cosmetics for >20 years without documented serious adverse events in published literature. Theoretical hypersensitivity risk exists for individuals with silk allergy, though cross-reactivity with purified peptide is low.
Safety information comes from cosmetic ingredient safety testing (INCI approved), manufacturer safety dossiers, and post-market surveillance in over 500 topical formulations globally. Minimal human clinical trial data exist specifically for efficacy in anti-aging applications, but extensive use in cosmetics establishes acceptable topical safety profile. Non-systemic bioavailability through skin means serious adverse events are inherently unlikely despite lack of formal drug-level safety studies.
Common Side Effects
Experienced by some users
Mild gastrointestinal discomfort
Slight nausea or stomach upset with oral administration, common with peptide supplements. Usually transient and self-limiting.
Management: Take with a small amount of food or water. Usually resolves within the first few days.
Increased urinary frequency initially
Temporary increase in urination frequency during the first few days as bladder smooth muscle tone normalizes and detrusor function adjusts.
Management: Normal part of the therapeutic process. Should stabilize within 5-7 days as bladder function normalizes.
Mild headache
Transient headache during the adjustment period, potentially related to changes in vascular tone from endothelin-1 normalization.
Management: Ensure adequate hydration. Usually self-limiting within 3-5 days. Standard analgesics may be used if needed.
Minor fatigue
Slight fatigue or drowsiness in the first few days of use as the body adapts to epigenetic changes in gene expression.
Management: Take in the morning. Usually resolves as the body adjusts to the bioregulatory effects.
Less Common
- •Injection site irritation
These typically resolve with continued use or dose adjustment.
Stop and Seek Help If
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Vesilute
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Vesilute should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Interactions
With other peptides
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
With medications
- !Alpha-1 adrenergic blockers at high doses without monitoring — potential additive effects on smooth muscle relaxation and blood pressure - Use with caution—discuss with your healthcare provider.
- !Anticholinergic medications for overactive bladder without medical guidance — overlapping mechanisms may produce excessive bladder relaxation - Use with caution—discuss with your healthcare provider.
- !Immunosuppressive medications — Vesilute's immunomodulatory effects (cytokine regulation) may interact unpredictably with immunosuppression - Use with caution—discuss with your healthcare provider.
With supplements
- ✓Multivitamins - Generally safe to take alongside Vesilute. Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
Does it
work?
Evidence Level
Moderate human trials
What to Expect
Days 1-10
What you might notice
- •No dramatic changes initially — epigenetic mechanisms require time for gene expression shifts
- •Possible slight increase in urinary frequency as detrusor function begins to normalize
- •Mild initial side effects (GI discomfort, headache) that resolve within days
- •The peptide-DNA interactions begin immediately but downstream protein changes take days to weeks
What's normal
- •Subtle or no noticeable effects during the first week — this is expected with bioregulatory peptides
- •Vesilute is working at the epigenetic level: binding DNA, modifying chromatin accessibility, and beginning to alter gene expression patterns
- •Anti-inflammatory effects (cytokine reduction) begin building during this period
What's next
- →Continue the full 20-30 day treatment course — benefits are cumulative
- →Begin tracking urinary symptoms (frequency, urgency, flow quality) for comparison
- →Chromatin reactivation and gene expression changes are building toward functional improvements
Week 2-4
What you might notice
- •Gradual improvement in urinary function — reduced urgency, improved flow, fewer nighttime awakenings
- •Decreased urinary frequency as bladder capacity normalizes
- •Reduced discomfort associated with chronic cystitis or prostatitis as inflammation decreases
- •Better quality of life related to urogenital function
What's normal
- •Pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) are significantly reduced by this point
- •Sirtuin-1 upregulation is supporting cellular repair in urogenital tissues
- •MMP-9 inhibition and Ki-67/CD98hc enhancement are shifting tissue balance toward regeneration
What's next
- →Complete the full course duration (20-30 days)
- →Benefits continue to develop after the course ends as epigenetic changes persist
- →Plan the next course in 2-6 months to reinforce and extend the bioregulatory effects
Month 1-6 (inter-course period)
What you might notice
- •Sustained improvements in urinary function from persistent epigenetic modifications
- •Ongoing tissue repair benefits from upregulated regeneration markers
- •Benefits may gradually diminish over 3-6 months, indicating readiness for the next treatment course
- •Each subsequent course typically builds on and extends the improvements from previous courses
What's normal
- •Epigenetic modifications persist beyond the active treatment period — the hallmark of Khavinson bioregulator therapy
- •Cyclical treatment every 2-6 months is the standard approach in Russian bioregulator protocols
- •Long-term users report cumulative improvements with each treatment course
What's next
- →Begin the next Vesilute course after 2-6 months for sustained bioregulatory benefits
- →Consider adding Prostamax or Ventfort as complementary bioregulators in rotation
- →Comprehensive anti-aging protocols may incorporate 4-6 different bioregulators used sequentially
Signs It's Working
Treatment Response
- ✓Improvement in the primary symptoms or condition being treated
- ✓Positive changes in relevant lab values or clinical markers
- ✓Consistent, stable response to Vesilute over time
- ✓Reduction in symptom frequency or severity
General Well-being
- ✓Improved energy levels and daily functioning
- ✓Better quality of life related to the treated condition
- ✓Manageable or absent side effects indicating good tolerance
- ✓Positive feedback from healthcare provider during check-ups
Not Seeing Results?
Common reasons
- •Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- •Insufficient time at target dose—most compounds need several weeks to show full benefits
- •Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- •Individual variation in response—genetics, metabolism, and other factors affect outcomes
- •Underlying conditions or medications interfering with absorption or effectiveness
- •Improper storage leading to degraded product—always verify proper storage conditions
Key Research
"The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19"
Linkova N, Khavinson V, Diatlova A, 2023
Finding: This study investigated the properties and effects of Vesilute, contributing to our understanding of its mechanism of action and potential therapeutic applications.
View Study"Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides"
Ashapkin V, Khavinson V, Shilovsky G, 2020
Finding: This study investigated the properties and effects of Vesilute, contributing to our understanding of its mechanism of action and potential therapeutic applications.
View Study"Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro"
Lin'kova NS, Drobintseva AO, Orlova OA, 2016
Finding: This study investigated the properties and effects of Vesilute, contributing to our understanding of its mechanism of action and potential therapeutic applications.
View Study"Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease"
Khavinson VK, Lin'kova NS, Umnov RS, 2021
Finding: This study investigated the properties and effects of Vesilute, contributing to our understanding of its mechanism of action and potential therapeutic applications.
View Study"Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis"
Kozlov KL, Bolotov II, Linkova NS, 2016
Finding: This study investigated the properties and effects of Vesilute, contributing to our understanding of its mechanism of action and potential therapeutic applications.
View StudyFrequently Asked Questions